HOXA9 and CD163 potentiate pancreatic ductal adenocarcinoma progression.

IF 4.6 Q2 MATERIALS SCIENCE, BIOMATERIALS ACS Applied Bio Materials Pub Date : 2024-10-26 DOI:10.1186/s13000-024-01563-5

Aiat Shaban Hemida, Mohamed Mohamady Ahmed, Mona Saeed Tantawy

{"title":"HOXA9 and CD163 potentiate pancreatic ductal adenocarcinoma progression.","authors":"Aiat Shaban Hemida, Mohamed Mohamady Ahmed, Mona Saeed Tantawy","doi":"10.1186/s13000-024-01563-5","DOIUrl":null,"url":null,"abstract":"Background: The role of HOXA9 requires investigations in pancreatic ductal adenocarcinoma (PDAC) as HOXA9 inhibitors are being developed. HOXA9 might attract CD163 expressed tumor associated macrophages (TAM) and could affect PDAC prognosis. This work aims to study the expression and relevance of HOXA9 and CD163 in PDAC progression.Materials and methods: Selected 98 PDAC and 98 adjacent non tumor tissues as a control group were immunostained with HOXA9 and CD163 antibodies.Results: PDAC displayed highly significant higher HOXA9 staining intensity, percent and H score values than control group. HOXA9 staining of PDAC cases showed significant associations with poor prognostic indicators including larger tumor size, higher grade and advanced stage. PDAC showed highly significant differences regarding CD163 macrophage-specific staining intensity, percent and H score values than control group. CD163 showed significant higher expressions with larger tumor size, higher histological grade and advanced stage group. HOXA9 staining in PDAC showed highly significant direct correlations with CD163 positive macrophages. Follow up of PDAC cases revealed that high median H score of HOXA9 and CD163 were significantly associated with worse overall survival. CD163 was an independent prognostic marker of worse survival.Conclusions: In conclusion, HOXA9 could potentiate PDAC progression by stimulating CD163 expressed TAM attraction in tumors. HOXA9 and CD163 could participate in PDAC therapy. HOXA9 and CD163 could be predictors of worse prognosis and shorter survival in PDAC.","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11514874/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13000-024-01563-5","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The role of HOXA9 requires investigations in pancreatic ductal adenocarcinoma (PDAC) as HOXA9 inhibitors are being developed. HOXA9 might attract CD163 expressed tumor associated macrophages (TAM) and could affect PDAC prognosis. This work aims to study the expression and relevance of HOXA9 and CD163 in PDAC progression.

Materials and methods: Selected 98 PDAC and 98 adjacent non tumor tissues as a control group were immunostained with HOXA9 and CD163 antibodies.

Results: PDAC displayed highly significant higher HOXA9 staining intensity, percent and H score values than control group. HOXA9 staining of PDAC cases showed significant associations with poor prognostic indicators including larger tumor size, higher grade and advanced stage. PDAC showed highly significant differences regarding CD163 macrophage-specific staining intensity, percent and H score values than control group. CD163 showed significant higher expressions with larger tumor size, higher histological grade and advanced stage group. HOXA9 staining in PDAC showed highly significant direct correlations with CD163 positive macrophages. Follow up of PDAC cases revealed that high median H score of HOXA9 and CD163 were significantly associated with worse overall survival. CD163 was an independent prognostic marker of worse survival.

Conclusions: In conclusion, HOXA9 could potentiate PDAC progression by stimulating CD163 expressed TAM attraction in tumors. HOXA9 and CD163 could participate in PDAC therapy. HOXA9 and CD163 could be predictors of worse prognosis and shorter survival in PDAC.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

HOXA9和CD163可促进胰腺导管腺癌的进展。

背景：由于正在开发 HOXA9 抑制剂，因此需要研究 HOXA9 在胰腺导管腺癌（PDAC）中的作用。HOXA9可能会吸引CD163表达的肿瘤相关巨噬细胞（TAM），并可能影响PDAC的预后。本研究旨在研究 HOXA9 和 CD163 在 PDAC 进展中的表达及其相关性：选取 98 例 PDAC 和 98 例邻近的非肿瘤组织作为对照组，用 HOXA9 和 CD163 抗体进行免疫染色：结果：与对照组相比，PDAC的HOXA9染色强度、百分比和H评分值均显著高于对照组。PDAC病例的HOXA9染色与预后不良指标（包括肿瘤体积较大、分级较高和分期较晚）有显著相关性。与对照组相比，PDAC病例的CD163巨噬细胞特异性染色强度、百分比和H评分值均有非常显著的差异。在肿瘤体积较大、组织学分级较高和晚期组中，CD163的表达明显较高。PDAC中的HOXA9染色与CD163阳性巨噬细胞有非常显著的直接相关性。对PDAC病例的随访显示，HOXA9和CD163的中位H评分越高，总生存率越低。CD163是生存率降低的独立预后标志：结论：总之，HOXA9可通过刺激肿瘤中CD163表达的TAM的吸引而促进PDAC的进展。HOXA9和CD163可参与PDAC的治疗。HOXA9和CD163可能是PDAC预后恶化和生存期缩短的预测因子。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊